Yale team says failed AstraZeneca drug shows promise in Alzheimer's

AstraZeneca's ($AZN) AZD0530 proved a disappointment as a new drug for solid tumors, but a Yale team says it may prove more effective in a new program for Alzheimer's. Working with NIH money designated to find new purposes for old, failed drugs, the Yale team says that AZD0530 tackles one of the key steps in the development of Alzheimer's--blocking the activation of the enzyme FYN, which interrupts the synaptic connections between brain cells needed to retain memories. It's now in a Phase IIa study for Alzheimer's at Yale. More from FierceBiotechResearch

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.